Peptide Library / Detail
B7-33
Half-life
Extended compared to native relaxin-2, with lipidated derivatives showing further improved stability
Delivery
Subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
B7-33 is a single B-chain derivative peptide analogue of human relaxin-2 (H2 relaxin) that acts as a functionally selective relaxin family peptide receptor 1 (RXFP1) agonist. It was developed to replicate the cardiovascular and anti-fibrotic benefits of relaxin while offering improved stability and reduced complexity compared to the full two-chain relaxin hormone. B7-33 has demonstrated vasoprotective, anti-fibrotic, and cardioprotective properties in preclinical research.
Usage
Research protocols typically involve subcutaneous administration. Dosing varies by application and animal model studied, with ongoing research to establish optimal human-equivalent doses. In preclinical cardiovascular studies, B7-33 has been administered chronically to assess long-term remodeling effects. Research applications focus on cardiac remodeling, fibrosis reduction, and vascular function.
Mechanism of Action
B7-33 selectively binds to and activates the relaxin family peptide receptor 1 (RXFP1), triggering intracellular signaling cascades that promote vasodilation, inhibit fibroblast activation and collagen deposition, and enhance extracellular matrix remodeling. Unlike full relaxin, B7-33 consists only of the B-chain component, which maintains receptor activation while demonstrating improved serum stability. The peptide reduces transforming growth factor-beta (TGF-β) signaling and inflammatory pathways involved in pathological fibrosis.
Benefits(7)
- Reduces cardiac fibrosis and adverse remodeling following myocardial infarction
- Demonstrates anti-fibrotic effects in renal and other tissue fibrosis models
- Replicates vasoprotective functions including improved endothelial function
- Reduces fibrotic encapsulation of implanted materials and medical devices
- Shows improved serum stability compared to native relaxin-2
- Attenuates pathological cardiac remodeling while preserving function
- Promotes extracellular matrix degradation and tissue remodeling
Side Effects(5)
- Limited human safety data currently available
- Potential hypotensive effects due to vasodilatory activity
- Theoretical risk of excessive matrix degradation with chronic use
- Safety profile in pregnancy and reproductive function not established
- Long-term cardiovascular effects in humans require further study